2025
PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Kumarakulasinghe N, Tey J, Sundar R. PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone. ESMO Gastrointestinal Oncology 2025, 7: 100109. DOI: 10.1016/j.esmogo.2024.100109.Peer-Reviewed Original ResearchAdvanced esophageal squamous-cell carcinomaPD-L1 expressionProgression-free survivalFirst-line chemotherapyPD-L1Overall survivalPredictive biomarkersKaplan-MeierKaplan-Meier (KM)Estimate time-to-event outcomesPatients treated with first-line chemotherapyNegative predictor of OSPhase III randomized trialRisk of tumor progressionProgression-free survival analysisPatients treated with chemotherapyCancer treated with chemotherapyNegative predictive biomarkerNon-significant increased riskPD-L1 subgroupsPositive predictive biomarkerEsophageal squamous-cell carcinomaPredictors of OSIndividual Patient Data Meta-AnalysisResponse to immunotherapyReal-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents
Chiang A, Madison R, Assaf Z, Fine A, Cao Y, Gjoerup O, Huang Y, Jin D, Hughes J, Antic V, Young A, Fabrizio D, Shames D, Maund S, Exarchos A, Lakhanpal S, Zuniga R, Pasquina L, Schulze K. Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents. JTO Clinical And Research Reports 2025, 100829. DOI: 10.1016/j.jtocrr.2025.100829.Peer-Reviewed Original ResearchSmall cell lung cancerReal-world progression-free survivalCirculating tumor DNAReal-world overall survivalCirculating tumor DNA dynamicsTumor fractionTumor response to immunotherapyLung cancer treated with chemotherapyCancer treated with chemotherapyProgression-free survivalResponse to immunotherapyCell lung cancerNon-small cellTumor imagingChemo-ImmunotherapyTumor responseOverall survivalTherapy initiationTumor DNAExploratory cohortTargeted therapyCtDNA quantificationTargeted agentsTreatment modalitiesTreatment regimens
2024
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual Patient Data Meta-AnalysisMedian Follow-UpPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData Meta-AnalysisLocoregional progressionNational Cancer InstituteDistant metastasis
2023
1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Barr N, Sundar R. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis. Annals Of Oncology 2023, 34: s873. DOI: 10.1016/j.annonc.2023.09.1471.Peer-Reviewed Original ResearchCancer treated with chemotherapyNegative predictive biomarkerPD-L1 expressionPD-L1Predictive biomarkersChemotherapy
2022
A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.
Argiris A, Flamand Y, Savvides P, Johnson J, Li S, Forastiere A, Burtness B. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Journal Of Clinical Oncology 2022, 40: 6026-6026. DOI: 10.1200/jco.2022.40.16_suppl.6026.Peer-Reviewed Original ResearchOverall survivalFirst-line treatmentMedian OSPrognostic factorsHazard ratioBone/liver metastasesRM-SCCHNFirst-lineFirst-line treatment of patientsMultivariate modelMetastatic squamous cell carcinomaPhase III randomized trialRisk factorsCancer treated with chemotherapyPlatinum-based chemotherapyECOG performance statusCooperative group trialsSquamous cell carcinomaHead and neckTumor cell differentiationTreatment of patientsPrognostic scoring modelCox proportional hazards modelsProportional hazards modelPrior radiation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply